Back to the main directory
EarningsReview / Equity
- Solar is in a Holding Pattern by BNP Paribas Exane
- EU OEMs seek 2 yr CO2 delay? (BBG) by BNP Paribas Exane
- Debating the big reset by BNP Paribas Exane
- Puuilo - Hold: Strong Q2 performance in a weak Finnish market by Nordea
- Considering combinations by BNP Paribas Exane
- Draghi’s brutal message by BNP Paribas Exane
- Orion - 2025 outlook warrants a breather by Danske Bank Equity Research
- Vetoquinol - Une Transition Un Peu Plus Marquée by MidCap Partners
- Robertet - Strong H1, more cautious outlook for H2 by MidCap Partners
- FDA approval of Apple’s Hearing Aids feature as OTC hearing aid software by BNP Paribas Exane
- Ping An Bank (000001 CH) by HSBC
- 泸州老窖（000568 CH） by HSBC
- FQ3’24 postview: Another complicated quarter by BNP Paribas Exane
- Jinjia Group (002191 CH) by HSBC
- INVEST SECURITIES - ASSYSTEM : Nos craintes sur Expleo confirmées - NEUTRE, OC 42€ (vs 48€) by Invest Securities
- INVEST SECURITIES - CARMAT : Objectif de CA finalement abaissé, visibilité limitée - ACHAT, OC 4,2€ (vs 7,6€) by Invest Securities
- INVEST SECURITIES - ATOS : Révision logique du BP, mais sera-t-elle la dernière ? VENTE, OC 0,01€ by Invest Securities
- Most Read Research - Week 6-12 September 2024 by BNP Paribas Exane
- Huace Film & TV (300133 CH) by HSBC
- 信达生物（1801 HK） by HSBC
- Non material data changes by BNP Paribas Exane
- Tigermed (300347 CH / 3347 HK) by HSBC
- Non material data changes by BNP Paribas Exane
- CDMO’s insolvency to impact EBITDA (< 1%), FY24 guidance range unch. by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- Computacenter (CCC LN) by HSBC
- Adobe Inc (ADBE US) by HSBC
- Divesting, deleveraging and derisking by BNP Paribas Exane
- Diagnosing the Pru problem by BNP Paribas Exane
- ChemoMetec - Sell/DKK 335 (Hold): A challenging path back to high growth by Nordea
- Rusta - Beats the heat on earnings but with low quality by Danske Bank Equity Research
- Acquisition in Brazil by BNP Paribas Exane
- Robertet - Gros premier semestre, plus prudent sur le S2 by MidCap Partners
- Vetoquinol - A Slightly More Pronounced Transition by MidCap Partners
- 平安银行（000001 CH） by HSBC
- Luzhou Laojiao Co Ltd (000568 CH) by HSBC
- VALE, GREEN STEEL, CLF, X, WEEKLY RECAP by BNP Paribas Exane
- 劲嘉股份（002191 CH） by HSBC
- Korean assets: a price one cannot turn down? by BNP Paribas Exane
- INVEST SECURITIES - ATOS : Dilution bien plus importante qu'anticipée - VENTE, OC 0,01€ by Invest Securities
- INVEST SECURITIES - BIOMERIEUX : Dynamique intarissable, objectifs relevés - ACHAT, OC 126€ (vs 123€) by Invest Securities
- FQ1 and FAD postview: USD100bn of revenues in sight by BNP Paribas Exane
- 华策影视（300133 CH） by HSBC
- The Weekly Checkout by BNP Paribas Exane
- Innovent Biologics (1801 HK) by HSBC
- Non material data changes by BNP Paribas Exane
- 泰格医药（300347 CH/3347 HK） by HSBC
- Konecranes - Guidance upgrade confirms good performance by Danske Bank Equity Research
- London Field Trip feedback by BNP Paribas Exane
- TMUS CMD - Pushbacks and Positioning by BNP Paribas Exane